Company intelligence / Profile preview
Bio-Path Holdings, Inc.
Bellaire, Texas, United Statesbiopathholdings.com ↗
- Ownership
- Public · BPTH
- Development stage
- Other
01
Overview
The company has multiple ongoing clinical trials. Their Phase 1/1b trial of BP1002 for AML showed a meaningful patient response with stable disease and significant reduction in blast count after one treatment cycle. Their Phase 2 trial for prexigebersen in AML is ongoing, and they've developed a molecular biomarker package to identify patients more likely to respond to treatment.
- Therapeutic areas
- OncologyEndocrinologyHematology
- Modalities
- RNAi nanoparticle drugsantisense oligodeoxynucleotidesDNA therapeutics
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Financials
- Market cap
- $15.1K
- Total revenue
- $0
- Enterprise value
- $533.1K
Beyond the preview
Go deeper on Bio-Path Holdings, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bio-Path Holdings, Inc..